{"id":"https://openalex.org/W3212978684","doi":"https://doi.org/10.1182/blood-2021-146976","title":"Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia","display_name":"Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3212978684","doi":"https://doi.org/10.1182/blood-2021-146976","mag":"3212978684"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-146976","doi":"https://doi.org/10.1182/blood-2021-146976","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-146976","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022077315","display_name":"Ugochinyere A. Emeribe","orcid":"https://orcid.org/0009-0000-8251-6163","observed_orcids":["https://orcid.org/0009-0000-8251-6163"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ugochinyere Emeribe","raw_affiliation_strings":["AstraZeneca, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110815937","display_name":"Priyanka Gaitonde","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Priyanka Gaitonde","raw_affiliation_strings":["AstraZeneca, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":null,"display_name":"Ling Cai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ling Cai","raw_affiliation_strings":["AstraZeneca, South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, South San Francisco, CA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"2633","last_page":"2633"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":0.9860000014305115},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.9670000076293945},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9810000061988831},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":1.0},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9829999804496765},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.8619999885559082},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9169999957084656},{"id":"https://openalex.org/keywords/bh3-mimetics","display_name":"BH3 mimetics","score":0.7900000214576721},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8209999799728394},{"id":"https://openalex.org/keywords/individual-patient-data","display_name":"individual patient data","score":0.5929999947547913},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.8109999895095825}],"concepts":[{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.9238024950027466},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.8930995464324951},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.8291636109352112},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7494262456893921},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.6972295045852661},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6577954292297363},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5911353826522827},{"id":"https://openalex.org/C2777609679","wikidata":"https://www.wikidata.org/wiki/Q5971015","display_name":"IGHV@","level":4,"score":0.5553749203681946},{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.50882488489151},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5067797303199768},{"id":"https://openalex.org/C2781442060","wikidata":"https://www.wikidata.org/wiki/Q425745","display_name":"Bendamustine","level":4,"score":0.4524584412574768},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.4451175332069397},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.31565791368484497},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.2538908123970032},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.19923073053359985},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.16429728269577026}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-146976","doi":"https://doi.org/10.1182/blood-2021-146976","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-146976","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389229579","https://openalex.org/W3157209850","https://openalex.org/W3097014789","https://openalex.org/W2999980976","https://openalex.org/W3011180414","https://openalex.org/W2970283563","https://openalex.org/W7163691533","https://openalex.org/W3110997092","https://openalex.org/W2987552010","https://openalex.org/W2992300027"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Acalabrutinib":[2],"(A)":[3],"and":[4,25,42,138,197,271,282,294,316,355,371,398,433,455,482,502,515,539,558,576,588,610,649,705],"ibrutinib":[5],"(I)":[6],"are":[7,229,578,634],"both":[8,586,608],"highly":[9],"effective":[10,629],"Bruton":[11],"tyrosine":[12],"kinase":[13],"inhibitors":[14],"(BTKi)":[15],"approved":[16,194],"for":[17,52,120,136,145,195,257,328,466,474,508],"the":[18,62,99,139,165,170,175,198,202,240,246,378,383,388,410,628,637,646,801],"treatment":[19,191],"of":[20,70,169,494,500,530,554,614,639,655,757,770],"chronic":[21],"lymphocytic":[22],"leukemia":[23],"(CLL)":[24],"given":[26],"as":[27,189,360,623,660],"continuous":[28],"treatments":[29],"until":[30],"disease":[31],"progression":[32],"or":[33,227],"unacceptable":[34],"toxicity.":[35],"Venetoclax":[36],"is":[37,192,600,617],"a":[38,53,76,116,305,321,581,603,624,671,761,774],"BH3":[39],"mimetic":[40],"compound":[41],"B-cell":[43],"lymphoma-2":[44],"inhibitor":[45],"prescribed":[46],"in":[47,57,75,109,245,280,377,425,447,492,498,645,760,773,786,793,800],"combination":[48],"with":[49,73,112,124,276,520,524,567,580,591,602,636,643,658],"obinutuzumab":[50,148],"(V+O)":[51],"fixed":[54],"(12-cycle)":[55],"duration":[56],"treatment-na\u00efve":[58,85,110],"CLL":[59,86,113],"patients.":[60],"Although":[61],"ELEVATE-RR":[63,640],"study":[64,81],"demonstrated":[65,115,272],"an":[66],"improved":[67],"safety":[68,118,330,583],"profile":[69,119,584],"A":[71,137,146,384,408,416,501,525,575,612,642],"compared":[72,123],"I":[74,171,386,507,587,609,644],"head-to-head":[77],"clinical":[78,269],"trial,":[79],"this":[80,190,615,668],"did":[82,420],"not":[83,187,193,413,421,618],"include":[84],"patients":[87,111,522,565],"(Byrd":[88],"et":[89,104,157,179,206,287],"al.":[90,158,180,207,288],"J":[91,289],"Clin":[92,290],"Oncol.":[93,291],"2021).":[94],"This":[95,344],"MAIC":[96,252,345,573,595,616],"builds":[97],"upon":[98],"published":[100,244,380],"analysis":[101,285,331],"by":[102,131],"Davids":[103],"al":[105],"(Leuk":[106],"Lymphoma.":[107],"2021)":[108,160],"(which":[114],"favorable":[117,582],"A-based":[121,656],"therapy":[122,657],"other":[125],"targeted":[126],"therapies":[127],"without":[128],"compromising":[129],"efficacy)":[130],"including":[132,619],"longer":[133,592],"follow-up":[134],"data":[135,144,236,348,352,357,364,368,373,666],"comparators.":[140],"Methods:":[141],"Individual":[142],"patient":[143,235],"\u00b1":[147],"(A+O)":[149],"from":[150,174,201,239,349,353,358,365,369,374,670],"ELEVATE-TN":[151],"(47":[152],"months":[153],"median":[154],"follow-up)":[155],"(Sharman":[156],"ASCO":[159],"were":[161,237,265,463,472,504,562],"weighted":[162,306,322],"to":[163,255,313,362,626,746],"match":[164],"aggregate":[166],"baseline":[167,212],"characteristics":[168],"monotherapy":[172],"arm":[173,200],"ALLIANCE":[176],"trial":[177,204],"(Woyach":[178],"NEJM.":[181],"2018)":[182],"(I":[183],"+":[184],"rituximab":[185],"was":[186,253,311,326,339,412],"included":[188,346,376],"CLL)":[196],"V+O":[199,418,589,659],"CLL-14":[203,359,375],"(Al-Sawaf":[205],"Lancet":[208],"Oncol":[209],"2020).":[210],"These":[211],"characteristics,":[213],"TP53":[214],"mutation,":[215],"serum":[216],"\u03b2":[217],"2":[218],"microglobulin,":[219],"ECOG,":[220],"IGHV":[221],"status,":[222],"del(11q),":[223],"CrCl,":[224],"Rai":[225],"stage":[226],"CLL-IPI,":[228],"potential":[230,621],"prognostic":[231],"variables":[232],"(PV).":[233],"Pseudo-individual":[234],"generated":[238],"digitized":[241],"Kaplan-Meier":[242],"curves":[243],"aforementioned":[247],"comparator":[248],"trials.":[249,261],"An":[250],"unanchored":[251],"conducted":[254],"adjust":[256],"these":[258,572,594],"PVs":[259,263,622],"between":[260],"The":[262,415],"selected":[264],"based":[266],"on":[267,571,667],"literature,":[268],"judgement,":[270],"statistically":[273,341],"significant":[274,423,445,470,604],"association":[275],"progression-free":[277],"survival":[278,318],"(PFS)":[279],"univariate":[281],"multivariate":[283],"regression":[284,324],"(Ahn":[286],"2020;":[292],"Eichorst":[293],"Hallek.":[295],"Hematol":[296,299],"Am":[297],"Soc":[298],"Educ":[300],"Prog.":[301],"2016).":[302],"After":[303],"matching,":[304],"Cox":[307],"proportional":[308],"hazard":[309],"model":[310,325],"used":[312,327],"analyze":[314],"PFS":[315,389,426,448,475],"overall":[317],"(OS)":[319],"while":[320],"logistic":[323],"comparative":[329],"(grade":[332],"\u22653":[333,496],"adverse":[334],"events":[335],"[AEs]).":[336],"Two-sided":[337],"p<0.05":[338],"considered":[340],"significant.":[342,414],"Results:":[343],"47-month":[347],"ELEVATE-TN,":[350,366],"38-month":[351],"ALLIANCE,":[354],"40-month":[356],"opposed":[361],"28-month":[363],"29-month":[367,372],"RESONATE-2,":[370],"previously":[379],"analysis.":[381],"In":[382],"vs":[385,417,443,468,506,549,585,607],"comparison,":[387],"(hazard":[390],"ratio":[391],"[HR]":[392],"0.83":[393],"[95%":[394,402,429,437,451,459,478,486],"CI":[395,403,430,438,452,460,479,487],"0.50,":[396],"1.37])":[397],"OS":[399,434,456,483],"(HR":[400,427,435,449,457,476,484],"0.69":[401],"0.37,":[404],"1.29])":[405],"numerically":[406],"favored":[407],"but":[409],"difference":[411],"comparison":[419],"show":[422],"differences":[424,446,471,491],"0.96":[428],"0.56,":[431],"1.65]":[432],"0.99":[436],"0.51,":[439],"1.91]).":[440],"For":[441,547],"A+O":[442,467,503,548,577,599],"I,":[444],"0.48":[450],"0.27,":[453],"0.88])":[454],"0.41":[458],"0.18,":[461],"0.91])":[462],"observed.":[464],"Similarly,":[465],"V+O,":[469,521,550],"observed":[473,505,563],"0.38":[477],"0.20,":[480],"0.73])":[481],"0.43":[485],"0.19,":[488],"0.99]).":[489],"Significant":[490],"rate":[493],"grade":[495],"AEs":[497],"favor":[499],"atrial":[509],"fibrillation,":[510],"hypertension,":[511],"decreased":[512,516],"neutrophil":[513],"count,":[514],"platelet":[517],"count.":[518],"Compared":[519],"treated":[523,566],"had":[526],"significantly":[527,551],"lower":[528,552],"rates":[529,553],"febrile":[531],"neutropenia,":[532,534,557],"leukopenia,":[533],"thrombocytopenia,":[535],"non-melanoma":[536,544,559],"skin":[537,545,560],"cancer,":[538],"secondary":[540],"primary":[541],"malignancies,":[542],"excluding":[543],"cancer.":[546],"infusion-related":[555],"reaction,":[556],"cancer":[561],"among":[564],"A+O.":[568],"Conclusions:":[569],"Based":[570],"results,":[574],"associated":[579,601],"while,":[590],"follow-up,":[593],"results":[596,638],"demonstrate":[597],"that":[598],"efficacy":[605],"benefit":[606],"V+O.":[611],"limitation":[613],"all":[620],"trade-off":[625],"conserve":[627],"sample":[630],"size.":[631],"Our":[632],"findings":[633],"consistent":[635],"comparing":[641],"relapsed":[647],"population":[648],"also":[650],"provide":[651],"insight":[652],"into":[653],"comparisons":[654],"we":[661],"await":[662],"more":[663],"definitive":[664],"prospective":[665],"question":[669],"phase":[672],"3":[673],"trial.":[674],"Figure":[675,677],"1":[676],"1.":[678],"Disclosures":[679],"Davids:":[680],"Genentech:":[681],"Consultancy,":[682,687,709,714,719,723,727,733,737],"Research":[683,688,692,710,715,720,724,728,734,738,745,777],"Funding;":[684,689,693,711,716,721,725,729,735,739],"Ascentage":[685],"Pharma:":[686,713,741],"Surface":[690],"Oncology:":[691],"AbbVie:":[694],"Consultancy;":[695,698,700,702,707,731,742,744,748],"Adaptive":[696],"Biotechnologies:":[697],"BeiGene:":[699],"Celgene:":[701],"Eli":[703],"Lilly":[704],"Company:":[706],"BMS:":[708],"MEI":[712,740],"TG":[717],"Therapeutics:":[718],"Pharmacyclics:":[722],"Verastem:":[726],"Janssen:":[730],"Novartis:":[732],"Astra-Zeneca:":[736],"Merck:":[743],"Practice:":[747],"Takeda:":[749],"Consultancy.":[750],"Emeribe:":[751],"AstraZeneca:":[752,765,780],"Current":[753,755,766,768,781,783,790],"Employment,":[754,767,782],"holder":[756,769,785,792],"stock":[758,771],"options":[759,772],"privately-held":[762,775],"company.":[763],"Gaitonde:":[764],"company,":[776],"Funding.":[778],"Cai:":[779],"equity":[784,791],"publicly-traded":[787,794],"company;":[788,795],"Google:":[789],"Celgene":[796],"Corporation:":[797],"Ended":[798],"employment":[799],"past":[802],"24":[803],"months.":[804]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-11-22T00:00:00"}